Passage Bio, Inc. (PASG) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is ...

Passage Bio (PASG) announced new interim results from the first six patients in its Phase 1/2 study for PBGM01 targeted at GM1 Gangliosidosis ((GM1)), Read full story here.

For PASG, shares are up 24.26% over the past week while the Zacks Medical - Biomedical and Genetics industry is up 3.78% over the same time period.

Fintel reports that on September 3, 2024, Rodman & Renshaw initiated coverage of Passage Bio (NasdaqGS:PASG) with a Buy recommendation. Analyst Price Forecast Suggests 940.03% Upside As of August ...

Passage Bio, Inc. (PASG) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is ...

Passage Bio, Inc. (PASG) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is ...

Passage Bio (NASDAQ:PASG) just reported results for the first quarter of 2024. Passage Bio reported earnings per share of -30 cents. This was above the analyst estimate for EPS of -36 cents. The ...